Sesen Bio Inc.

NASDAQ:SESN   3:58:30 PM EDT
0.52
0.00 (+0.21%)
Debt Financing / Related, Divestitures / Spin-offs, Regulatory

Sesen Bio Says Strategic Alternatives May Include Sale, A Merger

Published: 05/03/2022 12:44 GMT
Sesen Bio Inc. (SESN) - Sesen Bio Provides Strategic Update.
Sesen Bio Inc - Potential Strategic Alternatives to Be Explored and Evaluated During Review Process May Include Sale, a Merger.
Sesen Bio Inc - Potential Strategic Alternatives to Be Explored and Evaluated May Include Acquisition, a Strategic Partnership/ Licensing, Sale.
Sesen Bio Inc - Potential Strategic Alternatives to Be Explored and Evaluated May Include Or Divestiture of Some of Co's Proprietary Technologies.
Sesen Bio - Pending Decision to Undertake Any Strategic Alternative, Co to Continue Development Activities Accordance With Existing Business Strategy.
Sesen Bio Inc - Plan to Request Meeting With FDA in Coming Weeks to Align on Remaining Outstanding Items Related to Additional Phase 3 Clinical Trial.
Sesen Bio Inc - As of March 31, 2022, Co Had $169.8 Million in Cash and Cash Equivalents, No Outstanding Debt.